Current Report Filing (8-k)

Date : 07/01/2019 @ 1:01PM
Source : Edgar (US Regulatory)
Stock : aTyr Pharma Inc (LIFE)
Quote : 6.16  -0.9 (-12.75%) @ 9:30PM

Current Report Filing (8-k)




Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 28, 2019



(Exact name of registrant as specified in its charter)








(State or other jurisdiction

of incorporation)


(Commission File Number)


(IRS Employer

Identification No.)

3545 John Hopkins Court, Suite #250

San Diego, California





(Address of principal executive offices)




(Zip Code)

  Registrant’s telephone number, including area code: (858) 731-8389

Not Applicable

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share


The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      





Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Effective as of June 28, 2019, the aTyr Pharma, Inc. (the “Company”) Board of Directors (the “Board”) appointed Jane A. Gross, Ph.D. and Svetlana Lucas, Ph.D. to the Board.  Dr. Gross was appointed as a Class II director, and will serve until the Company’s annual meeting of stockholders in 2020 or until her successor is duly elected and qualified or her earlier resignation or removal.  Dr. Lucas was appointed as a Class III director, and will serve until the Company’s annual meeting of stockholders in 2021 or until her successor is duly elected and qualified or her earlier resignation or removal.  As non-employee directors, Drs. Gross and Lucas will receive cash and equity compensation pursuant to the Company’s current non-employee director compensation policy.

Neither Dr. Gross or Dr. Lucas are a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understanding between either of Dr. Gross or Dr. Lucas and any other persons pursuant to which Dr. Gross or Dr. Lucas were selected as a director.

In connection with their appointment as directors, Drs. Gross and Lucas each entered into the Company’s standard form of indemnification agreement and were each granted an option to purchase 32,000 shares (on a pre-reverse stock split basis) of the Company’s Common Stock at an exercise price to be the closing price of the Company’s common stock on the Nasdaq Capital Market on June 28, 2019, which will vest in equal monthly installments during the three years following the effective date of his appointment to the Board, subject to such individual’s continued service on the Board.

On June 28, 2019, John D. Mendlein, Ph.D. provided the Company with notice of his resignation from the Board, effective as of June 28, 2019.  Dr. Mendlein’s decision to resign was not a result of a disagreement with management regarding the Company’s operations, policies, practice or otherwise.  Dr. Mendlein has served on the Board since 2010.  Dr. Mendlein will continue to serve as a strategic advisor to the Company pursuant to the terms of that certain Strategic Advisor Agreement, dated November 1, 2017, between the Company and Dr. Mendlein.  

Item 8.01 Other Events.

On July 1, 2019, the Company issued a press release announcing the newly appointed directors.  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.












/s/ Jill M. Broadfoot



Jill M. Broadfoot



Chief Financial Officer




Date: July 1, 2019








aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart

1 Year : From Jan 2019 to Jan 2020

Click Here for more aTyr Pharma Charts.

aTyr Pharma (NASDAQ:LIFE)
Intraday Stock Chart

Today : Friday 17 January 2020

Click Here for more aTyr Pharma Charts.

Latest LIFE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.